UL Solutions Inc.
ULS
$73.44
-0.26%
UL Solutions Inc. is a global leader in testing, inspection, and certification (TIC) services, helping customers across industrial and consumer end-markets demonstrate product safety, quality, and regulatory compliance, complemented by a smaller risk and compliance software and advisory business. Spun out of the nonprofit UL Enterprise and listed on the NYSE in April 2024, the company occupies a premium position in the Specialty Business Services industry, leveraging the century-old UL safety mark as a trusted, quasi-regulatory brand that creates high switching costs and recurring, regulation-driven demand. The current investor narrative centers on whether UL Solutions can sustain mid-single-digit organic growth and margin expansion as a newly public company while digesting a sharp de-rating in its shares, which have fallen from triple-digit levels in May 2026 to the low-$70s by late October despite a recent rebound. Debate now hinges on the durability of TIC demand amid industrial softness, the trajectory of profitability after a noisy Q2 with a large non-operating gain, and whether the stock's premium multiple is justified given decelerating momentum relative to the broader market.…
ULS
UL Solutions Inc.
$73.44
Investment Opinion: Should I buy ULS Today?
Rating: Hold with a constructive bias. The core thesis is that UL Solutions is a high-quality, regulation-driven TIC franchise with expanding margins and a de-rated valuation, but near-term momentum and cash conversion concerns warrant patience. The analyst consensus is 'buy' (mean 1.85) with an average target of $96.57, implying +31.5% upside, yet the stock's -7.2% one-year performance and -20.36% relative strength suggest the market is not yet convinced.
Supporting evidence: forward PE of 28.2x is well below the trailing 48.7x, implying 42% earnings growth is expected; gross margin expanded to 51.1% from 49.0% YoY; operating margin improved to 18.4% from 17.9%; and ROE of 25.8% is strong for the industry. TTM FCF of $436M yields ~2.75%, covering the modest 0.66% dividend. The PS ratio of 5.19x and EV/EBITDA of 23.7x are premium to peers but at the low end of the stock's own post-IPO range, suggesting the de-rating has already priced in much of the bad news.
Key risks that could invalidate the thesis: persistent working-capital drag keeping FCF conversion below 50% of EBITDA; revenue growth decelerating below 4%; and further multiple compression if the forward PE fails to converge. This Hold would upgrade to Buy if FCF conversion improves and revenue growth accelerates above 6%, or downgrade to Sell if gross margin falls below 49% or the stock breaks below $63.17. Valuation verdict: fairly valued to modestly undervalued relative to its own history, but still at a premium to peers, offering asymmetric risk/reward for patient investors.
Sign up to view all
ULS 12-Month Price Forecast
UL Solutions presents a balanced risk/reward: the stock has de-rated to the low end of its historical valuation band (forward PE 28.2x vs. 48.7x trailing), margins are expanding, and analysts see 31.5% upside, but revenue growth is stuck at ~5% and cash conversion is weak. The neutral stance reflects the tension between a premium-quality franchise trading at a reasonable forward multiple and the lack of a near-term catalyst to reverse the relative underperformance. An upgrade to bullish would require evidence of accelerating revenue growth above 6% and improving FCF conversion; a downgrade to bearish would follow a break below the $63.17 support or a gross margin decline below 49%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on UL Solutions Inc.'s 12-month outlook, with a consensus price target around $96.57 and implied upside of +31.5% versus the current price.
Average Target
$96.57
0 analysts
Implied Upside
+31.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$79 - $120
Analyst target range
Coverage is solid, with 12 analysts and a consensus recommendation of "buy" (mean rating of 1.85 on a 1–5 scale where lower is more bullish). The average target price of $96.57 implies roughly +31.5% upside from the current $73.44, a notably bullish signal given the stock's -7.2% one-year performance. Consensus 2027 EPS of $2.88 and revenue of $3.72 billion underpin that optimism, and the bullish tilt is reinforced by recent actions: UBS upgraded to Buy from Neutral in July 2026, while Baird, Wells Fargo, and Citigroup have maintained Outperform/Overweight/Neutral stances through the Q2 print.
The target range of $79.00 to $120.00 is wide — a spread of roughly 52% around the average — signaling meaningful dispersion in analyst conviction. The high target of $120 assumes multiple re-expansion toward prior highs alongside accelerating margin capture and continued mid-single-digit organic growth, while the low target of $79 (still above the current price) prices in a more conservative scenario of modest growth and persistent industrial softness without a full re-rating. Notably, even the low target sits ~7.6% above the current price, suggesting analysts view the selloff as overdone; however, the clustering of Neutral ratings from Citigroup and JP Morgan indicates the bullish consensus is not unanimous, and the wide spread warrants position-sizing discipline given the elevated uncertainty.
Bulls vs Bears: ULS Investment Factors
The bear case currently has stronger near-term evidence: the stock is in a sustained downtrend with -20.36% relative strength versus the S&P 500 over one year, trading at just 23% of its 52-week range, and cash conversion remains a concern. However, the bull case is supported by tangible margin expansion (gross margin up 210bps YoY), a de-rated valuation at the low end of its historical band, and unanimous analyst optimism with a $96.57 average target. The single most important tension is whether the premium multiple (23.7x EV/EBITDA) can be justified by margin-driven earnings growth (forward PE 28.2x vs. trailing 48.7x) or whether decelerating mid-single-digit revenue growth will force further de-rating. Resolution hinges on the next few quarters delivering the earnings expansion analysts expect without further working-capital drag.
Bullish
- Analyst consensus sees 31.5% upside: All 12 covering analysts have a consensus 'buy' rating (mean 1.85) with an average target of $96.57, implying +31.5% upside from $73.44. Even the lowest target of $79 sits 7.6% above the current price, suggesting the selloff is viewed as overdone.
- Margin expansion is real and multi-quarter: Gross margin rose to 51.1% in Q2 2026 from 49.0% a year earlier and 47.9% in Q1 2025, while operating margin improved to 18.4% from 17.9%. This demonstrates operating leverage in the asset-light TIC model even as revenue growth stays mid-single-digit.
- Valuation de-rated to low end of history: Forward PE of 28.2x and PS of 5.19x sit in the lower half of the post-IPO range (PE 20.6x–59.7x, PS 10.2x–25.1x). The 42% gap between trailing PE (48.7x) and forward PE (28.2x) signals expected earnings growth, not deterioration.
- Defensive, regulation-driven business model: Beta of 0.707 implies ~30% less volatility than the market, and the UL safety mark creates high switching costs. Revenue grew 5.15% YoY to $816M in Q2 2026, with recurring compliance demand underpinning stability through industrial cycles.
Bearish
- Persistent relative underperformance vs. market: ULS is down 7.23% over one year versus the S&P 500's +13.13%, a relative strength of -20.36%. Over six months it has fallen 18.57% against a +6.45% market gain, and the stock sits at just 23% of its 52-week range ($63.17–$107.54).
- Premium multiple leaves little room for error: EV/EBITDA of 23.7x and P/B of 12.56x are rich for a mid-single-digit grower, and the negative PEG ratio (-79.3) reflects a distorted earnings base. Any deceleration in organic growth or margin slippage could trigger further multiple compression.
- Cash conversion lags reported profitability: TTM free cash flow of $436M is well below the ~$1.1B annualized EBITDA, and Q2 saw a -$121M working capital drag. FCF yield of ~2.75% is modest for a premium-valued stock, making cash conversion a key risk to the thesis.
- Growth is stable but not accelerating: Revenue growth of 5.15% YoY in Q2 2026 is consistent with the prior quarters ($758M Q1 2026, $789M Q4 2025), showing no inflection. Without acceleration, the stock relies on multiple re-rating rather than fundamental momentum to reach analyst targets.
ULS Technical Analysis
ULS is in a sustained downtrend that has only recently begun to stabilize. The stock is down -7.23% over the past year and -18.57% over six months, a stark underperformance versus the S&P 500's +13.13% one-year gain (relative strength of -20.36%). At $73.44, the shares sit at roughly 23% of the 52-week range of $63.17–$107.54, meaning price is in the lower quartile of its annual band — closer to a value-opportunity zone than a momentum extension, though the persistent lower highs argue against calling a durable bottom yet.
Short-term momentum has turned sharply positive and is diverging from the longer-term trend. The stock has rallied +12.33% over the past month versus a -1.02% decline in SPY, producing a relative strength of +13.35% — a notable inflection after -14.07% over three months and -9.23% year-to-date. This one-month surge against a negative one-year trend is characteristic of mean reversion off an oversold base rather than a confirmed trend reversal; the bounce began near the September lows around $64 and has reclaimed the $70 handle, but volume of roughly 972K shares is unremarkable and does not yet confirm institutional accumulation.
Key technical levels are well defined. Support rests at the 52-week low of $63.17, with the September consolidation zone near $64–$66 as the immediate floor; a breakdown below $63 would signal a resumption of the primary downtrend and likely trigger further de-rating. Resistance sits at the 52-week high of $107.54, with intermediate supply near the $85–$90 area where the July breakdown occurred. The stock's beta of 0.707 implies roughly 30% less volatility than the market, which is favorable for defensive position sizing but also means the recent +12% move is outsized relative to its typical trading range — a sign of genuine sentiment shift rather than routine noise.
Beta
0.71
0.71x market volatility
Max Drawdown
-39.0%
Largest decline past year
52-Week Range
$63-$108
Price range past year
Annual Return
-7.2%
Cumulative gain past year
| Period | ULS Return | S&P 500 |
|---|---|---|
| 1m | +12.3% | -1.5% |
| 3m | -14.1% | +2.8% |
| 6m | -18.6% | +6.8% |
| 1y | -7.2% | +12.2% |
| ytd | -9.2% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ULS Fundamental Analysis
Revenue is growing at a steady but modest pace. Q2 2026 revenue of $816 million rose 5.15% year-over-year from $776 million in Q2 2025, extending a consistent mid-single-digit trajectory ($758M in Q1 2026, $789M in Q4 2025, $783M in Q3 2025). Segment mix shows Industrial at $402 million and Consumer at $362 million driving the core TIC franchise, with Risk & Compliance Software contributing $52 million — a small but higher-margin adjunct. The growth trend is stable rather than accelerating, implying the investment case rests on regulatory-driven recurring demand and operating leverage rather than cyclical revenue acceleration.
Profitability is robust and margins are expanding. Q2 2026 net income reached $246 million (a 30.1% net margin, though flattered by a $188 million non-operating gain that lifted pre-tax income to $338 million), with gross margin of 51.1% versus 49.0% in Q2 2025 and 47.9% in Q1 2025 — a clear multi-quarter expansion. Operating margin of 18.4% in Q2 2026 compares favorably to 17.9% a year earlier, and the trailing operating margin of 17.1% with a 49.1% gross margin is consistent with a high-quality services model. Normalizing for the one-time gain, EPS of $1.22 versus $0.45 in the prior-year quarter still reflects solid underlying earnings power.
Financial health is sound but cash conversion warrants monitoring. Debt-to-equity of 0.66 and a current ratio of 1.32 indicate moderate leverage and adequate liquidity, while ROE of 25.8% and ROA of 12.3% are strong for the industry. Free cash flow TTM of $436 million against a $15.85 billion market cap yields roughly 2.75%, and Q2 operating cash flow of $160 million less $69 million capex produced $91 million of FCF — enough to fund the modest $29 million quarterly dividend and $57 million of debt repayment internally. The main caveat is working-capital drag: Q2 saw a -$121 million change in working capital, and the $436 million FCF figure is well below the ~$1.1 billion of annualized EBITDA, suggesting cash conversion is the metric to watch.
Quarterly Revenue
$816000000.0B
2026-06
Revenue YoY Growth
+5.1%
YoY Comparison
Gross Margin
51.1%
Latest Quarter
Free Cash Flow
$436000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ULS Overvalued?
Because ULS is profitable (net income positive), the PE ratio is the appropriate primary metric. The stock trades at a trailing PE of 48.7x versus a forward PE of 28.2x — a wide gap that implies the market expects meaningful earnings growth, consistent with consensus EPS of $2.88 versus the trailing figure distorted by the low reported EPS base. The forward multiple of 28.2x is the more economically meaningful anchor, and the 42% compression from trailing to forward signals that analysts anticipate substantial margin-driven earnings expansion.
Relative to the Specialty Business Services industry, ULS commands a clear premium. Its PS ratio of 5.19x and EV/Sales of 4.75x sit above typical sector levels, while EV/EBITDA of 23.7x and a P/B of 12.56x reflect the asset-light, high-return nature of the TIC model. The premium is defensible given gross margins near 49–51%, operating margins of 17%, and ROE of 25.8% — well above the average industrial services firm — but the 23.7x EV/EBITDA leaves limited room for execution missteps, and the negative PEG ratio (-79.3) reflects the distorted trailing earnings base rather than a genuine growth discount.
Historically, ULS has traded in a wide valuation band since its 2024 IPO. Its PE has ranged from roughly 20.6x (Q2 2024) to 59.7x (Q4 2025), and its PS ratio has spanned about 10.2x to 25.1x; the current PS of 5.19x and forward PE of 28.2x place the stock in the lower half of its own historical range, consistent with the sharp price decline. This suggests the market has already de-rated the shares substantially — either a value opportunity if fundamentals hold, or a warning that growth expectations are being reset lower. The P/B of 12.56x, near the low end of its post-IPO band, reinforces that multiple compression, not earnings deterioration, has driven the drawdown.
PE
48.7x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 19x~47x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on cash conversion and earnings quality. TTM free cash flow of $436M is well below the ~$1.1B annualized EBITDA, and Q2 2026 saw a -$121M working capital drag, meaning reported profits are not translating proportionally into cash. The $188M non-operating gain in Q2 inflated net income to $246M (30.1% net margin), so underlying earnings power is lower than headline figures suggest. Additionally, revenue growth of 5.15% YoY is modest and stable rather than accelerating, leaving the premium valuation dependent on continued margin expansion (gross margin 51.1%, operating margin 18.4%) that could stall if industrial demand softens.
Market and competitive risks include valuation compression and sector rotation. At 23.7x EV/EBITDA and 12.56x P/B, ULS trades at a premium to typical Specialty Business Services peers, leaving limited room for execution missteps. The stock's beta of 0.707 offers some defensiveness, but its -20.36% one-year relative strength versus the S&P 500 shows it has been out of favor; a rotation away from premium defensives could prolong the de-rating. The wide analyst target range ($79–$120, a 52% spread) signals disagreement about growth durability, and neutral ratings from Citigroup and JP Morgan indicate the bullish consensus is not unanimous.
Worst-case scenario: a renewed industrial slowdown compresses organic growth below 4%, working-capital drag persists, and the forward PE fails to converge toward the trailing multiple, triggering further multiple compression. In that chain, the stock could retest its 52-week low of $63.17, representing a -14.0% decline from $73.44. A more severe outcome, such as a broad market correction combined with an earnings miss, could push shares toward the $60 area, a -18% to -20% drawdown, consistent with the stock's max drawdown of -38.96% from its 2026 peak.
FAQ
The most severe risk is cash conversion: TTM FCF of $436M is only ~40% of annualized EBITDA, and Q2 2026 saw a -$121M working capital drag, which could worsen if industrial demand weakens. Second, valuation compression risk is high given the 23.7x EV/EBITDA premium; a rotation away from defensives could push the multiple below 20x. Third, revenue growth is stuck at ~5% (Q2 2026: 5.15% YoY), and any deceleration below 4% would likely trigger estimate cuts. Fourth, earnings quality is distorted by the $188M non-operating gain in Q2, masking underlying profitability. Ranked by severity: cash conversion, valuation, growth deceleration, earnings quality.
The 12-month forecast has three scenarios: bull (30% probability, target $96.57–$120), base (50%, target $79–$96.57), and bear (20%, target $63.17–$79). The base case is most likely, assuming revenue growth holds at 4-6% and margins remain above 50%, leading the stock toward the analyst average target of $96.57. The bull case requires acceleration to 6-7% growth and FCF improvement, while the bear case assumes industrial weakness and a retest of the $63.17 low. The key assumption behind the base case is that forward PE remains in the high-20s without major re-rating.
ULS appears fairly valued to modestly undervalued relative to its own history but still at a premium to peers. The forward PE of 28.2x is well below the trailing 48.7x and sits in the lower half of the post-IPO range (20.6x–59.7x), while the PS of 5.19x is far below the historical high of 25.1x. However, EV/EBITDA of 23.7x and P/B of 12.56x remain above typical Specialty Business Services levels. The market is pricing in ~42% earnings growth (forward vs. trailing PE), which is achievable if margins continue expanding, but leaves little room for disappointment.
ULS offers a favorable risk/reward for long-term investors: the stock trades at $73.44, 31.5% below the analyst average target of $96.57, and even the lowest target of $79 implies 7.6% upside. The forward PE of 28.2x is reasonable for a company with 25.8% ROE and expanding gross margins (51.1%), and the 0.707 beta provides downside protection. However, the -20.36% one-year relative strength and weak FCF conversion ($436M vs. ~$1.1B EBITDA) mean near-term upside may be limited. It is a good buy for patient investors with a 12-18 month horizon who can tolerate volatility, but not for momentum traders.
ULS is better suited for long-term investment (minimum 12-18 months) given its defensive beta (0.707), regulation-driven recurring revenue, and modest dividend yield of 0.66%. The stock's recent +12.33% one-month rally against a -7.23% one-year decline suggests mean-reversion volatility that is difficult to trade short-term, and the wide analyst target range ($79–$120) indicates uncertain near-term direction. Long-term holders can benefit from margin expansion and multiple normalization toward the $96.57 average target, while short-term traders face elevated risk of a retest of the $63.17 low. A suggested minimum holding period is 12 months to allow earnings growth to materialize.